Difference between revisions of "Part:BBa K5366067"
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
− | <partinfo> | + | <partinfo>BBa_K5366045 short</partinfo> |
− | + | ||
− | + | ||
+ | AJC7 five-point mutant | ||
+ | <h1>Construction</h1> | ||
+ | Primers for the S125D point mutation were designed, and PCR was conducted using pET-28a(+)-AJC7 as a template (Fig. 1). Following the PCR reaction, DpnI demethylation was performed. To verify the digestion, 5 µL of the reaction was analyzed using nucleic acid gel electrophoresis. After confirming the correctness of the PCR product, recovery was carried out to obtain the single-point mutant plasmid. | ||
+ | The concentration of the single-site mutant plasmid was measured, and it was subsequently transformed into <i>E. coli</i> BL21 (DE3) cells. The cells were incubated in inverted culture at 37°C for 14 hours. From the transformed colonies, single colonies were selected for colony PCR. Following nucleic acid electrophoresis verification, the corresponding colonies with the correct bands were transferred to LB (Kan) liquid medium for preservation. This step completed the S125D single-point mutation process. | ||
+ | After the successful creation of the S125D single-point mutant plasmid, this plasmid was further mutated to obtain the S125D/T181A two-point mutant plasmid, following the same single-point mutation protocol. Subsequently, the S125D/T181A two-point mutant plasmid was mutated to generate the S125D/T181A/H342L three-point mutant plasmid. This process continued with the S125D/T181A/I129T three-point mutant plasmid and the S125D/T181A/I129T/L140P four-point mutant plasmid. Finally, the S125D/T181A/I129T/L140P four-point mutant plasmid was mutated to create the S125D/T181A/I129T/L140P/H342L five-point variant mutant plasmid, which was then transfected into <i>E. coli</i> BL21 (DE3) and verified by nucleic acid electrophoresis (Figure 2). | ||
+ | <html> | ||
+ | <style> | ||
+ | .bild {max-width: 60% ; height: auto;} | ||
+ | </style> | ||
+ | <p> | ||
+ | <img class="bild" src="https://static.igem.wiki/teams/5366/part/wudian45.png"><br> | ||
+ | <i><b> Fig.1 Mapping of mutant plasmids <br><br></b></I> | ||
+ | <div class="unterschrift"><bFig. 1 Construction of pMTL-Pfba-Bs2 recombinant plasmid</b> | ||
+ | </div> | ||
+ | </p> | ||
+ | </html> | ||
+ | <html> | ||
+ | <style> | ||
+ | .bild {max-width: 60% ; height: auto;} | ||
+ | </style> | ||
+ | <p> | ||
+ | <img class="bild" src="https://static.igem.wiki/teams/5366/part/fig-2-nucleic-acid-gel-diagram-of-colony-pcr-4-point-mutation-on-the-left-and-5-point-mutation-on-the-right.png"><br> | ||
+ | <i><b> Fig.2 Nucleic acid gel diagram of colony PCR (4-point mutation on the left and 5-point mutation on the right) <br><br></b></I> | ||
+ | <div class="unterschrift"><bFig. 1 Construction of pMTL-Pfba-Bs2 recombinant plasmid</b> | ||
+ | </div> | ||
+ | </p> | ||
+ | </html> | ||
+ | <h1>Product Analysis</h1> | ||
+ | The mutant and wild-type strains were subjected to activation and amplification culture, followed by a series of protein purification processes to extract the target proteins, as described in [Experimental]. The volume of the purified enzyme solution required for the 500 μL reaction system was determined based on the protein concentration indicated in [Experimental]. The final fructose concentration in the system was set at 100 g/L, along with the addition of 10 µL of Ni<sup>2+</sup> as a catalyst. The reaction was conducted at 70°C for 5 hours, and the final product was analyzed using High-Performance Liquid Chromatography (HPLC) (Figure 3). | ||
+ | <html> | ||
+ | <style> | ||
+ | .bild {max-width: 60% ; height: auto;} | ||
+ | </style> | ||
+ | <p> | ||
+ | <img class="bild" src="https://static.igem.wiki/teams/5366/part/30.png"><br> | ||
+ | <i><b> Fig.30 The concentrations of tagatose in WT, S125D, S125D/T181A, S125D/T181A/I129T, S125D/T181A/I129T/L140PS125D/T181A/I129T/L140P/H342L after reacting with 100g/L fructose substrate for 5 h <br><br></b></I> | ||
+ | <div class="unterschrift"><bFig. 1 Construction of pMTL-Pfba-Bs2 recombinant plasmid</b> | ||
+ | </div> | ||
+ | </p> | ||
+ | </html> | ||
+ | <h1>Result</h1> | ||
+ | To further enhance substrate transformation capabilities, we conducted five point mutations on AJC7, specifically substituting S125D, T181A, I129T, L140P, and H342L . The results indicated that the concentration of the product following these mutations was significantly increased compared to that of the wild-type strain. | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
Line 10: | Line 50: | ||
<!-- --> | <!-- --> | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
− | <partinfo> | + | <partinfo>BBa_K5366045 SequenceAndFeatures</partinfo> |
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
===Functional Parameters=== | ===Functional Parameters=== | ||
− | <partinfo> | + | <partinfo>BBa_K5366045 parameters</partinfo> |
<!-- --> | <!-- --> |
Revision as of 13:49, 28 September 2024
AJC7/S125D/T181A/ I129T/L140P/ H342L-6xHis
AJC7 five-point mutant
Construction
Primers for the S125D point mutation were designed, and PCR was conducted using pET-28a(+)-AJC7 as a template (Fig. 1). Following the PCR reaction, DpnI demethylation was performed. To verify the digestion, 5 µL of the reaction was analyzed using nucleic acid gel electrophoresis. After confirming the correctness of the PCR product, recovery was carried out to obtain the single-point mutant plasmid. The concentration of the single-site mutant plasmid was measured, and it was subsequently transformed into E. coli BL21 (DE3) cells. The cells were incubated in inverted culture at 37°C for 14 hours. From the transformed colonies, single colonies were selected for colony PCR. Following nucleic acid electrophoresis verification, the corresponding colonies with the correct bands were transferred to LB (Kan) liquid medium for preservation. This step completed the S125D single-point mutation process. After the successful creation of the S125D single-point mutant plasmid, this plasmid was further mutated to obtain the S125D/T181A two-point mutant plasmid, following the same single-point mutation protocol. Subsequently, the S125D/T181A two-point mutant plasmid was mutated to generate the S125D/T181A/H342L three-point mutant plasmid. This process continued with the S125D/T181A/I129T three-point mutant plasmid and the S125D/T181A/I129T/L140P four-point mutant plasmid. Finally, the S125D/T181A/I129T/L140P four-point mutant plasmid was mutated to create the S125D/T181A/I129T/L140P/H342L five-point variant mutant plasmid, which was then transfected into E. coli BL21 (DE3) and verified by nucleic acid electrophoresis (Figure 2).
Fig.1 Mapping of mutant plasmids
Fig.2 Nucleic acid gel diagram of colony PCR (4-point mutation on the left and 5-point mutation on the right)
Product Analysis
The mutant and wild-type strains were subjected to activation and amplification culture, followed by a series of protein purification processes to extract the target proteins, as described in [Experimental]. The volume of the purified enzyme solution required for the 500 μL reaction system was determined based on the protein concentration indicated in [Experimental]. The final fructose concentration in the system was set at 100 g/L, along with the addition of 10 µL of Ni2+ as a catalyst. The reaction was conducted at 70°C for 5 hours, and the final product was analyzed using High-Performance Liquid Chromatography (HPLC) (Figure 3).
Fig.30 The concentrations of tagatose in WT, S125D, S125D/T181A, S125D/T181A/I129T, S125D/T181A/I129T/L140PS125D/T181A/I129T/L140P/H342L after reacting with 100g/L fructose substrate for 5 h
Result
To further enhance substrate transformation capabilities, we conducted five point mutations on AJC7, specifically substituting S125D, T181A, I129T, L140P, and H342L . The results indicated that the concentration of the product following these mutations was significantly increased compared to that of the wild-type strain. Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 501
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 1003
- 1000COMPATIBLE WITH RFC[1000]